Human PBMC treated with PHA for 48 hr were stained with (A) Rabbit Anti-Human 4-1BB/TNFRSF9/CD137 Monoclonal Antibody (Catalog # MAB8382) or (B) Rabbit IgG control antibody (Catalog # MAB1050) followed by APC-conjugated Goat-anti Rabbit IgG secondary antibody (Catalog # F0111) and Mouse anti-Human CD3 PE-conjugated Monoclonal Antibody (Catalog # FAB100P). View our protocol for Staining Membrane-associated Proteins.

Human 4-1BB/TNFRSF9/CD137 Antibody Stimulates IL-2 Secretion in Human T Cells.

Rabbit Anti-Human 4-1BB/TNFRSF9/CD137 Monoclonal Antibody (Catalog # MAB8382) co-stimulates IL-2 secretion in human T cells in the presence of anti-CD3 in a dose-dependent manner, as measured by the Human IL-2 Quantikine ELISA Kit (Catalog # D2050). The ED50 for this effect is typically 1-10 µg/mL.

Applications for Human 4-1BB/TNFRSF9/CD137 Antibody

Application

Recommended Usage

Agonist Activity

Measured by its ability to co-stimulate IL-2 secretion by human T cells in the presence of anti-CD3. The ED₅₀ for this effect is typically 1-10 μg/mL.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/10⁶ cells
Sample: Human PBMC treated with PHA for 48 hr

Formulation, Preparation, and Storage

Purification

Protein A or G purified from cell culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: 4-1BB/TNFRSF9/CD137

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4⁺, CD8⁺, memory CD8⁺, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8⁺ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells (9, 10).
4-1BB activation enhances CD8⁺ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

References

Wang, C. et al. (2009) Immunol. Rev. 229:192.
Schwarz, H. et al. (1993) Gene 134:295.
Alderson, M.R. et al. (1994) Eur. J. Immunol. 24:2219.
Wen, T. et al. (2002) J. Immunol. 168:4897.
Pulle, G. et al. (2006) J. Immunol. 176:2739.
Zheng, G. et al. (2004) J. Immunol. 173:2428.
Kim, D. et al. (2008) J. Immunol. 180:2062.
Lee, S. et al. (2008) Nat. Immunol. 9:917.
Choi, B.K. et al. (2009) J. Immunol. 182:4107.
Nishimoto, H. et al. (2005) Blood 106:4241.
Saito, K. et al. (2004) J. Biol. Chem. 279:13555.
Lee, S. et al. (2005) J. Immunol. 174:6803.
Ma, B.Y. et al. (2005) Blood 106:2002.
Choi, B.K. et al. (2010) J. Immunol. 185:1404.
Kim, C. et al. (2011) Diabetes 60:3159.
Michel, J. et al. (1998) Eur. J. Immunol. 28:290.
Salih, H.R. et al. (2001) J. Immunol. 167:4059.

Alternate Names

41BB, CD137, ILA, TNFRSF9

Entrez Gene IDs

3604 (Human); 21942 (Mouse); 500590 (Rat); 102127961 (Cynomolgus Monkey)

Gene Symbol

TNFRSF9

UniProt

Q07011

Additional 4-1BB/TNFRSF9/CD137 Products

Product Documents for Human 4-1BB/TNFRSF9/CD137 Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human 4-1BB/TNFRSF9/CD137 Antibody

For research use only

Citations
Reviews

Calculators
Flow Cytometry

Human 4-1BB/TNFRSF9/CD137 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB8382

Key Product Details

Validated by

Species Reactivity

Applications

Label

Antibody Source

View all 4-1BB/TNFRSF9/CD137 Antibodies »

Product Specifications

Immunogen

Specificity

Clonality

Host

Isotype

Endotoxin Level

Scientific Data Images for Human 4-1BB/TNFRSF9/CD137 Antibody

Detection of 4-1BB/TNFRSF9/CD137 in Human PHA-treated PBMC by Flow Cytometry.